81 results
DEFM14A
HARP
Harpoon Therapeutics Inc
8 Feb 24
Proxy related to merger
7:00am
to the continued research, development and commercialization of Harpoon’s product candidates, including with respect to HPN328, HPN217 and HPN601, while also … or licensors or any Third Party with which the Company has entered into a Contract that relates to the research, development, supply, manufacturing, testing
PREM14A
HARP
Harpoon Therapeutics Inc
29 Jan 24
Preliminary proxy related to merger
4:52pm
research, development and commercialization of Harpoon’s product candidates, including with respect to HPN328, HPN217 and HPN601, while also accounting … of the Company’s licensees or licensors or any Third Party with which the Company has entered into a Contract that relates to the research, development, supply
DEFA14A
HARP
Harpoon Therapeutics Inc
8 Jan 24
Additional proxy soliciting materials
8:04am
or any Third Party with which the Company has entered into a Contract that relates to the research, development, supply, manufacturing, testing … over the research, development, manufacture or exploitation of any Company Product, or any successor agency to any of the foregoing.
“Representatives
8-K
EX-2.1
HARP
Harpoon Therapeutics Inc
8 Jan 24
Entry into a Material Definitive Agreement
8:01am
Party with which the Company has entered into a Contract that relates to the research, development, supply, manufacturing, testing, distribution, import … generated or used in relation to the research, testing, development, use, handling, packaging, storage, safety, efficacy, reliability
424B5
HARP
Harpoon Therapeutics Inc
24 Nov 23
Prospectus supplement for primary offering
2:01pm
capital and general corporate purposes, including research and development expenses and capital expenditures. Pending our use of the net proceeds from … of Proceeds
We currently intend to use the net proceeds from this offering for working capital and general corporate purposes, including research
8-K
EX-99.1
9patlsgv
9 Nov 23
Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:11pm
8-K
EX-99.1
wzepd
9 Aug 23
Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:25pm
424B5
zpfrbou0 fkt0ve1
16 May 23
Prospectus supplement for primary offering
6:09am
8-K
EX-99.1
i0rns2x
11 May 23
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
9:07pm
PRE 14A
2tjz sc8s9w
14 Apr 23
Preliminary proxy
4:54pm
8-K
EX-99.1
jn7o70h3oykbidxatjy
14 Nov 22
Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results
5:17pm
8-K
EX-99.1
ozu1u8n0jo
10 Aug 22
Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:14pm